Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy T Batchelor

Showing results (81-90 of 268) with videos related to

Pageof 27
Sort By:
Oncotarget|November 8, 2017
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastomaIsabel Arrillaga-Romany, Andrew S Chi, Joshua E Allen, et al.
Journal of Neuropathology and Experimental Neurology|December 6, 2006
Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survivalMasahiro Mizoguchi, Rebecca A Betensky, Tracy T Batchelor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2013
Reply to B. Freidlin et alLorenzo Trippa, Eudocia Q Lee, Patrick Y Wen, et al.
Nature Reviews. Neuroscience|July 24, 2007
Angiogenesis in brain tumoursRakesh K Jain, Emmanuelle di Tomaso, Dan G Duda, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 1, 2016
Reliable estimation of microvascular flow patterns in patients with disrupted blood-brain barrier using dynamic susceptibility contrast MRIMikkel Bo Hansen, Anna Tietze, Jayashree Kalpathy-Cramer, et al.
Neuro-Oncology|February 17, 2010
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitorsBrian J Scott, Eudocia C Quant, Margaret B McNamara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Bayesian adaptive randomized trial design for patients with recurrent glioblastomaLorenzo Trippa, Eudocia Q Lee, Patrick Y Wen, et al.
International Journal of Radiation Oncology, Biology, Physics|June 28, 2005
Genetic analyses for predictors of radiation response in glioblastomaHelen A Shih, Rebecca A Betensky, Molly V Dorfman, et al.
Cancer|April 4, 2017
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remissionZachariah DeFilipp, Shuli Li, Areej El-Jawahri, et al.
Neurology|July 26, 2015
Standard chemoradiation for glioblastoma results in progressive brain volume lossMorgan J Prust, Kourosh Jafari-Khouzani, Jayashree Kalpathy-Cramer, et al.
Pageof 27

Showing results (81-90 of 268) with videos related to

Sort By:
Pageof 27
Oncotarget|November 8, 2017
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastomaIsabel Arrillaga-Romany, Andrew S Chi, Joshua E Allen, et al.
Journal of Neuropathology and Experimental Neurology|December 6, 2006
Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survivalMasahiro Mizoguchi, Rebecca A Betensky, Tracy T Batchelor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2013
Reply to B. Freidlin et alLorenzo Trippa, Eudocia Q Lee, Patrick Y Wen, et al.
Nature Reviews. Neuroscience|July 24, 2007
Angiogenesis in brain tumoursRakesh K Jain, Emmanuelle di Tomaso, Dan G Duda, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 1, 2016
Reliable estimation of microvascular flow patterns in patients with disrupted blood-brain barrier using dynamic susceptibility contrast MRIMikkel Bo Hansen, Anna Tietze, Jayashree Kalpathy-Cramer, et al.
Neuro-Oncology|February 17, 2010
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitorsBrian J Scott, Eudocia C Quant, Margaret B McNamara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Bayesian adaptive randomized trial design for patients with recurrent glioblastomaLorenzo Trippa, Eudocia Q Lee, Patrick Y Wen, et al.
International Journal of Radiation Oncology, Biology, Physics|June 28, 2005
Genetic analyses for predictors of radiation response in glioblastomaHelen A Shih, Rebecca A Betensky, Molly V Dorfman, et al.
Cancer|April 4, 2017
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remissionZachariah DeFilipp, Shuli Li, Areej El-Jawahri, et al.
Neurology|July 26, 2015
Standard chemoradiation for glioblastoma results in progressive brain volume lossMorgan J Prust, Kourosh Jafari-Khouzani, Jayashree Kalpathy-Cramer, et al.
Pageof 27